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EAD early allograft dysfunction 
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MP machine perfusion 
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RCT randomised controlled trial 
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Abstract 
The increased demand for organs has led to the increased usage of “higher-risk” kidney and liver 
grafts. These grafts from donation after circulatory death or expanded criteria donors are more 
susceptible to preservation injury and have a higher risk of unfavourable outcomes. Dynamic, 
instead of static preservation could allow for organ optimisation, offering a platform for viability 
assessment, active organ repair and resuscitation. Ex situ machine perfusion and in situ regional 
perfusion in the donor are emerging as potential tools to preserve and resuscitate vulnerable grafts. 
Preclinical findings have ignited clinical organ preservation research that investigates dynamic 
preservation, its various modes (continuous, pre-implantation) and temperatures (hypothermic, sub-
, or normothermic). This review outlines the current status of dynamic preservation of kidney and 
liver grafts and describes on-going research and emerging clinical trials. 
 
 
Introduction 
The shortage of suitable organs for transplantation has resulted in the increased use of “higher-risk” 
grafts. Kidneys and livers from donation after circulatory death (DCD) donors or recovered from 
brain dead expanded criteria donors (ECD) are particularly susceptible to the harmful effects of 
warm and cold ischaemia and reperfusion injury. Consequently, these organs have an increased 
probability to develop initial graft dysfunction (delayed graft function (DGF) in kidney, early allograft 
dysfunction (EAD) in liver), primary non-function (PNF), biliary complications, and decreased long-
term graft survival (1-5). Optimised organ preservation strategies protecting these vulnerable grafts 
should allow organ viability assessment and resuscitation, thus reducing the unnecessary discard of 
organs. For this purpose, novel dynamic preservation strategies are being developed. 
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This overview outlines the current status of dynamic preservation of kidney and liver grafts and 
describes on-going research and emerging clinical trials. These trials were identified by a thorough 
search of available online registry databases.  
Table S1: Non-exhaustive list of planned or on-going clinical trials investigating dynamic preservation 
of kidney or liver that were not registered in an online clinical trial registry at the time of writing this 
manuscript. 
Supplementary Appendix 1 outlines the search strategy. Suppl. Table 1 shows a non-exhaustive list 
of currently non-registered trials identified through our network. 
 
From dynamic to static storage and back 
The concept of dynamic organ preservation was developed by Carrel and Lindbergh in the 1930s (6, 
7). Some thirty years later, after extensive work by pioneering groups led by Belzer (8-10) and Starzl 
(11-13), hypothermic dynamic preservation using plasma or blood-based solutions became a clinical 
reality. Dynamic preservation was the only way to preserve deceased organs until static cold storage 
(SCS) solutions became available (14-16). SCS offered a simple and effective way to preserve and 
transport organs, and soon became the most commonly used storage method. Recently, with 
increasing use of “higher-risk” grafts, there has been a resurgence of interest in dynamic 
preservation strategies. These could offer optimised organ preservation and real-time graft viability 
assessment whilst offering a platform for delivery of conditioning agents to repair damaged organs 
resulting in improved organ quality and utilisation. 
Features and modalities of dynamic preservation 
During dynamic preservation, recirculating perfusate (either acellular or blood-based) is 
continuously pumped through the organ vasculature. The perfusate can be non-oxygenated or 
oxygenated. A heat exchanger regulates temperature from hypothermia via subnormothermia to 
normothermia. Machine perfusion (MP) perfuses the organ ex situ, after it has been procured, 
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cannulated and connected to a pump (Fig. 1A). Continuous MP (from procurement to implantation) 
or pre-implantation MP (after a period of SCS and just before transplantation) are most commonly 
used (Fig. 2). Dynamic preservation can also begin before organ procurement by recirculating donor 
blood or a preservation solution in situ, after cannulation of the aorta/iliac arteries and vena 
cava/iliac veins (Fig. 1B). The abdominal compartment is isolated from the thorax by a balloon in, or 
a clamp on, the descending thoracic aorta, preventing cardiac and cerebral perfusion. This technique 
is also called abdominal regional perfusion (RP). 
Key elements determining dynamic preservation modalities are temperature (Fig. 2) and perfusion 
settings. Hypothermic dynamic preservation aims to slow down cellular metabolism and counteract 
undesirable and detrimental effects of ischaemia. It combines low temperature (4-10°C) with an 
acellular colloid-containing preservation solution, in the majority of cases using the Na-
gluconate/hydroxyethyl starch machine perfusion solution developed by Belzer et al. (17). There is 
some evidence that hypothermic dynamic preservation should be pressure- and not flow-controlled, 
using low pressures to avoid pressure-related injury (18-20). Pulsatile renal artery perfusion (25-30 
mmHg) is best for the kidney (20-26). The liver is perfused through the portal vein with a continuous 
flow, which in most circuits is pressure-controlled (3-5 mmHg, sometimes achieved by gravity) and 
occasionally flow-controlled (19, 27-33). It is not entirely clear whether portal perfusion alone is 
sufficient. Maintaining the peri-biliary vascular plexus seems of vital importance in the prevention of 
ischaemic-type biliary strictures (34). As mainly the hepatic artery supplies this plexus, some authors 
have advocated dual perfusion (portal vein and hepatic artery) (34). On the other hand, it seems that 
cold portal vein perfusion allows perfusion of the intra- and extra biliary vascular supply (35). To 
date, clinical trials have either used single pressure-controlled portal vein perfusion (30, 32), or non-
pulsatile flow-controlled dual perfusion (27, 31). 
Normothermic dynamic preservation (35-37°C) aims to restore normal cellular processes whilst 
facilitating viability assessment (36, 37). Normothermic preservation mandates an oxygenated 
perfusate with an oxygen carrier (usually red blood cells). Compared to hypothermic conditions, 
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where in the event of pump failure the graft is essentially cold-stored, an organ in a normothermic 
system is vulnerable to warm ischaemia should machine failure occur. Higher, near-physiological 
pressures are used for arterial perfusion of kidney (70-85 mmHg) (38-40) and liver (60-105 mmHg) 
(41-44). Pressure-controlled pumping of pig kidneys resulted in improved renal perfusion and better 
preserved structural integrity whereas flow-control caused diffuse and global glomerular destruction 
(40). 
Subnormothermic dynamic preservation (20-25°C) aims to avoid cold-induced injury without 
increasing metabolism to a level where intense oxygenation requires an oxygen carrier. Both 
acellular and cellular perfusates have been used (45-49). Pressure settings used for perfusion are set 
at 40 mmHg for kidney (49), 4-8 mmHg for portal vein, and 25-70 mmHg for hepatic artery (46-48, 
50). 
Controlled oxygenated rewarming, i.e. slowly rewarming a SCS organ to 20°C, aims to avoid abrupt 
temperature changes. Indeed, a possibly underestimated side effect of quickly rewarming an organ 
from hypo- to (sub)normothermic conditions may cause a “heat-shock” leading to mitochondrial 
dysfunction (51). 
Ex situ dynamic preservation 
Kidney 
Non-oxygenated hypothermic machine perfusion 
Non-oxygenated hypothermic MP (HMP) of the kidney, at low perfusion pressures (20-30 mmHg), 
has been shown to reduce DGF, and may improve graft survival (52). The largest randomised 
controlled trial (RCT) comparing SCS with continuous HMP of deceased donor kidneys using the 
LifePort (Organ Recovery Systems, Itasca, IL, USA) showed an overall reduced risk of DGF and a 
survival benefit, the latter most pronounced in ECD kidneys (21, 24). This portable device uses 
conventional roller-pump technology to generate a pressure-controlled pulsatile flow. Continuous 
HMP of DCD III (circulatory arrest after withdrawal of treatment) kidneys also resulted in a 
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decreased risk of DGF, but no impact on graft survival could be demonstrated (22). A parallel trial, 
also using the LifePort, did not demonstrate a reduction in DGF for DCD III kidneys (23). The use of 
both continuous and pre-implantation HMP in the latter may be the reason for the discrepancy 
between these trials. It has been suggested that relatively short periods of HMP (<4h) following long 
periods of SCS in DCD kidneys has reduced or no benefit compared to continuous HMP (53). 
Although Watson and colleagues are comparing continuous and pre-implantation HMP to SCS in two 
on-going trials (Table 1), there are currently no RCTs comparing continuous with pre-implantation 
HMP. 
Furthermore, it is possible that the length of HMP and its protective effect, may be different for 
different kidney types. Recent large registry analyses (>90,000 kidneys) have shown that in standard 
criteria kidneys, HMP reduces the risk of DGF compared to SCS irrespective of very short or very long 
CIT (54). In the same study, the risk of DGF was reduced for ECD kidneys with CIT>6h only, and in the 
case of DCD with CIT 6-24h only (54). Possibly an effect of shorter pumping times for ECD and DCD 
may have been missed due to lower numbers in the analyses, however, if this is not the case, then it 
suggests that these kidneys need to be pumped for at least 6h to benefit from HMP. Nevertheless, 
as CIT is a well-established predictor of DGF (3), a balance between minimising CIT and any potential 
benefits of HMP is required. To date, there is a lack of evidence that HMP allows longer duration of 
CIT. It seems that just a few hours of HMP, as long as the total CIT is not extended, can have a 
positive impact on early graft function compared to SCS. Additionally, published studies have 
reported no robust tools for viability assessment during HMP. Although previous studies have shown 
that increased vascular resistance and high perfusate injury marker concentrations are risk factors 
for DGF, they are not accurate enough to predict long-term outcomes or justify kidney discard (55, 
56). The development of novel biomarker identification platforms, such as proteomics and 
metabolomics, may allow better assessment. 
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Oxygenated hypothermic machine perfusion 
Oxygenation during HMP appears to be beneficial, as several preclinical studies have shown that 
cellular metabolism is slower but not at standstill and respiration continues during HMP resulting in 
oxidative stress (57, 58). Recent comparative porcine studies have demonstrated that, particularly in 
DCD, oxygenated continuous HMP improves early kidney graft function (59-61). In DBD settings it 
seems that a short period of oxygenated pre-implantation HMP could be sufficient to improve 
creatinine clearance when compared to SCS, possibly as effective as continuous oxygenated HMP 
(62, 63). The ideal oxygen tension, providing balance between benefit of oxygen and risk of 
increased production of oxygen free-radical species, remains unknown (60, 64). 
The effect of oxygenated HMP is being investigated in two RCTs initiated by the Consortium on 
Organ Preservation in Europe (COPE) (Table 1) using the Kidney Assist (Organ Assist, Groningen, The 
Netherlands). The Kidney Assist oxygenates the preservation solution and uses a centrifugal pump to 
generate a pressure-controlled pulsatile flow. COPE-COMPARE randomises one kidney from DCD III 
≥50y donors to oxygenated continuous HMP, the other to non-oxygenated continuous HMP. The 
trial is powered to demonstrate a difference in glomerular filtration 1y post-transplantation, with 
DGF and graft survival as secondary endpoints (Suppl. Appendix 2). In COPE-POMP, powered to 
demonstrate a difference in 1y graft survival, ECD kidneys are randomised upon arrival in the 
recipient centre to a minimum of 2h pre-implantation oxygenated HMP versus continued SCS (Suppl. 
Appendix 3). 
 
Normothermic machine perfusion 
A short period of normothermic MP (NMP) immediately prior to implantation has been found to 
improve kidney graft function, replenish ATP and reduce injury in a number of large animal models 
(36). A pilot clinical study compared 18 ECD kidneys that received 1h of pre-implantation blood-
based NMP with 47 matched SCS-controls. Remarkably low DGF rates were seen with pre-
implantation NMP (5,6% vs. 36,2%) (38). Currently, there are no registered on-going RCTs comparing 
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pre-implantation NMP to SCS. In contrast to HMP, kidney function can be evaluated during NMP by 
assessing macroscopic appearance of blood perfusion, renal blood flow and urine output (65, 66), 
but proof of concept of transplanting kidneys that were discarded and subsequently resuscitated by 
pre-implantation NMP has not yet been reported. Developing and validating tools assessing graft 
quality, predictive of transplant outcome, are needed to aid decision-making on whether to utilise or 
discard. 
 
Subnormothermic machine perfusion and controlled oxygenated rewarming 
Continuous subnormothermic machine perfusion (SMP) of DCD porcine kidneys has demonstrated 
improved creatinine clearance and preservation of structural integrity compared to continuous 
oxygenated HMP and SCS (49). Three hours of controlled oxygenated rewarming (COR) following 18h 
SCS enhanced creatinine clearance compared to continuous or pre-implantation HMP in a pig 
reperfusion model (51). Clinical use of SMP or COR in kidney transplantation has not yet been 
reported. 
 
Liver 
Hypothermic machine perfusion 
Experimental evidence shows that livers can be preserved by low pressure oxygenated HMP (or 
hypothermic oxygenated perfusion (HOPE)), using either continuous or pre-implantation perfusion 
(33). Oxygenated HMP reduces ischaemia-reperfusion injury and protects against biliary injury in 
preclinical models, however, there is no evidence yet that HMP can extend liver preservation times 
(29, 67). HMP of discarded human livers confirmed feasibility and safety of the technique (28, 68-
70). The Columbia group was the first to report the transplantation of 20 DBD livers preserved by 
pre-implantation HMP compared to matched SCS-controls (27). Pre-implantation HMP provided safe 
preservation in this pilot study with low EAD rates (5% vs. 25% of SCS livers). Guarrera et al. recently 
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reported on transplanting “orphan” livers -refused for transplantation by numerous centres- after 
pre-implantation HMP achieving reduced EAD rates, less biliary complications and shorter hospital 
stay compared to matched SCS-controls (31). 
The initial clinical experience of pre-implantation HMP of eight DCD livers by the Zürich group, 
showing feasibility of the technique with no evidence of ischaemic cholangiopathy eight months 
post-transplant despite extended DCD criteria (30) was recently expanded. Dutkowski et al. 
transplanted 25 DCD livers after pre-implantation oxygenated HMP and compared these to a 
matched cohort of 50 SCS DCD livers where they showed a reduced rate of intra-hepatic 
cholangiopathy at 1y follow-up and improved 1-year graft survival for pumped vs. SCS livers (32). 
Further studies comparing pre-implantation HMP with SCS have been announced (Table 2), some 
using single portal vein perfusion, others targeting dual perfusion. The Columbia system relies on 
dual flow-controlled perfusion with low pressures and continuous flow over portal vein and hepatic 
artery, the Zürich team applies pressure-controlled portal vein perfusion with continuous flow. The 
Zürich group have used both the ECOPS and the Liver Assist device for this purpose (Organ Assist, 
Groningen, The Netherlands). There are no trials exploring continuous HMP, however, Guarrera et 
al. suggest that prolonged SCS prior to HMP may negatively affect outcomes, therefore they 
encourage the development of a portable device. 
Adequate perfusate oxygenation seems necessary to protect the liver against ischaemia-reperfusion 
injury (71) although the ideal oxygen tension is unknown. Findings are inconsistent and a balance 
between beneficial effects of oxygen and production of radical oxygen species is likely to be 
important (71, 72). There is also debate whether active oxygenation (e.g. by an oxygenator, bubbling 
oxygen through the perfusate) is needed in the hypothermic setting, as Guarrera et al. report 
perfusate oxygen tensions >120mmHg in an open system without active oxygenation (27). 
Viability assessment during HMP is largely unexplored. Bile is not produced during HMP and 
although perfusate transaminases might correlate with graft injury, data from large clinical trials is 
needed to determine the value of HMP as a tool to predict outcome (27, 28, 73, 74). 
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Normothermic machine perfusion 
NMP simulates in vivo conditions and requires dual perfusion through hepatic artery and portal vein 
at physiological flows. It is thought to enable organ viability assessment (75, 76), reduce PNF, 
improve early graft function, and reduce ischaemic cholangiopathy by improved perfusion and 
preservation of the peri-biliary vascular plexus and peri-biliary glands (37, 41, 42). 
After numerous preclinical studies showing benefit of continuous NMP, a phase I study in the UK 
showed that prolonged continuous NMP with the portable Metra device (OrganOx, Oxford, UK) is 
feasible and safe (77). Twenty livers, of which 10 had high-risk profiles, were successfully 
transplanted with 6 month survival similar to that of 40 matched controls. Currently, a large phase III 
RCT is comparing continuous NMP using the Metra with SCS within COPE (Table 2, Suppl. Appendix 
4). The primary outcome is peak AST in the first seven days post-transplant (as a risk factor for graft 
survival) and the trial will also assess organ discard rates, PNF, EAD, ischaemic cholangiopathy on 
MRCP at 6 months, and graft and patient survival. Two trials with a different NMP liver device (OCS 
Liver) developed by TransMedics (Andover, MA, USA) have been started (Table 2), one is a safety 
study, the other an RCT with EAD as the primary outcome. Another RCT comparing NMP with SCS is 
running in Cleveland, USA, using a home-made circuit and targeting EAD as primary endpoint (Table 
2). 
The first case report using pre-implantation NMP of a human liver followed by successful 
transplantation has recently been published (44). Another case report describes a discarded liver 
successfully transplanted after assessment by pre-implantation NMP, with the decision to transplant 
made on the basis of normalisation of lactate (<2mmol/L) and bile production by the graft (78). 
These two parameters are judged as important markers, although additional research in large trials 
is needed to confirm this. Animal studies in DCD settings have suggested that continuous NMP is 
superior to pre-implantation reconditioning with NMP (37), however, if pre-implantation NMP 
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would prove non-inferior to continuous NMP, perhaps for a certain category of donor livers, this 
may offer logistical benefits whilst viability-assessment might still be possible (75, 78). 
 
Subnormothermic machine perfusion and controlled oxygenated rewarming 
Animal survival, liver function and bile duct preservation has been shown to be better after SMP 
than SCS in rat and pig models (45, 48, 79-82). Although SMP has not been used clinically, discarded 
livers can be supported by SMP with adequate flow rates, bile production and various biochemical 
parameters as potential surrogates for organ viability whilst histological analysis reveals no 
additional injury due to SMP (46, 47). 
Slowly rewarming the liver during COR to 20°C over 3h by pumping hepatic artery and portal vein 
has been shown to improve tissue energetics and histological appearance in a pig model (50). The 
first clinical COR-application of 6 high-risk, “orphan” DBD livers showed feasibility of COR with good 
function at 3 months compared to historical SCS-controls (83). 
 
In situ dynamic preservation or abdominal regional perfusion 
Regional perfusion (RP) of abdominal organs in DCD donors applies extracorporeal membrane 
oxygenation to deliver oxygen after a period of warm ischaemia. Hypothermic RP (HRP) reduces 
metabolic activity and requirements whereas Normothermic RP (NRP) may support the restoration 
of cellular processes by constant supply of oxygen and substrates in a near-physiological way (84). 
HRP in DCD has shown overall good kidney graft survival (>85%) but PNF could not be avoided and 
high rates of DGF (up to 75%) have been reported (84). The largest reported series of 320 DCD I+II 
(failed resuscitation outside or inside the hospital) kidney transplants shows an 87% 1-year graft 
survival (85). HRP (at 4-10°C) of livers has not been reported. NRP in DCD III has also shown good 
kidney graft survival with lower DGF rates (between 8% and 42%) (84, 86). 
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NRP of DCD II+III livers shows a wide range of graft survival rates (43%-91%) but acceptable patient 
survival (71%-91%) although PNF and ischaemic cholangiopathy incidences are higher than in 
recipients of DBD livers (84). 
 
Mechanisms of injury and repair during machine perfusion 
It is not known how dynamic preservation exerts its beneficial effects but perfusion likely helps to 
maintain a healthy endothelium, replenish ATP and it might even alter the organ’s immunogenicity 
(87, 88). Increased NO-dependent vasodilation and improved cortical microcirculation at reperfusion 
regulated through improved eNOS phosphorylation has been demonstrated in HMP-preserved DCD 
porcine kidneys (89). Moreover, a degree of vascular shear stress, that plays a critical role in normal 
vascular function, is maintained by the pulsatile flow of HMP, which could have an anti-inflammatory 
effect through the activation of flow-dependent genes (26, 90). 
Oxygenation during HMP has been shown to restore ATP content in kidney (61) and liver (33). In the 
liver, oxygenated pre-implantation HMP reversibly suppresses mitochondrial oxidative metabolism 
after cold preservation decreasing the mitochondrial release of reactive oxygen species upon 
reperfusion with several fold deactivation of numerous intracellular and extracellular pathways, 
including the host inflammatory response (19, 88, 91). Little is known about the working 
mechanisms of SMP and NMP besides the attempt to maintain a physiological environment. For 
blood-based perfusion there is evidence that the absence of leucocytes and platelets limits the 
inflammatory response and reduces apoptosis (36). A comparison of pre-implantation HMP with 
pre-implantation NMP of rat DCD livers that were SCS for 4h showed improved survival of both 
techniques compared to continued SCS after 30 min donor warm ischaemia time. However, when 
donor warm ischaemia time was 60 min, pre-implantation HMP resulted in improved survival (92). 
Multi-platform -omics studies and combination with computational biology will allow the use of an 
integrated approach to identify new pathways of injury and repair during organ preservation (93). 
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This will also ease identification of ways to improve dynamic preservation through development of 
targeted interventions. 
 
How to move forward? 
Dynamic preservation has the potential to improve (abdominal) organ preservation. However, there 
are many questions that remain unanswered today. Dynamic preservation techniques should not 
only be compared, they should also be evaluated in the light of other optimisation strategies such as 
e.g. donor hypothermia (94). Furthermore, it has become clear that organs with a different baseline 
risk will benefit from different preservation methods and graft-tailored conditioning should be the 
focus of future research. The use of dynamic preservation to resuscitate grafts, not only by restoring 
oxygen and nutrient flow, but also by actively targeting repair is underexplored as yet. Nevertheless, 
the addition of specific drugs, gene or cell therapy to an isolated organ and not to a patient is very 
attractive and has the potential to increase the number of transplantable organs. 
Much like organ donor intervention trials (95), organ preservation trials pose many regulatory, legal, 
ethical, and logistical challenges and those unique to organ preservation trials. At which stage and 
from whom should consent for research be sought as intended recipients may change following the 
preservation phase (e.g. due to a positive cross-match or recipient non-transplantability)? How 
should re-offering of these organs occur when randomisation and treatment of the organ has 
perhaps already started whilst there remains the inevitable pressure of time? If discarded organs 
seem to perform well during organ preservation, should they then be re-offered and how should this 
be done? To facilitate organ preservation research a debate between regulatory authorities and the 
transplant community is needed. Additionally, financial climate and device costs make it challenging 
to run investigator driven trials independent from the industry. Nevertheless, the search for 
optimised graft-tailored preservation and repair is crucial and as important as managing acute 
rejection was in the early days of transplantation: it deserves to be tackled with high priority and the 
same urgency. 
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Figure Legends 
Figure 1: Classical build-up of an ex vivo (Panel A) and in vivo (Panel B) dynamic preservation circuit. 
Perfusate is pumped through the organ vasculature by a pump (usually a roller or centrifugal pump). 
Addition of a heat-exchanger allows to vary the temperature, an oxygenator can be added to the 
circuit to oxygenate the perfusate. In case of hypothermic dynamic preservation the organ and 
reservoir are often topically cooled with ice without the need of a heat exchanger. During ex vivo 
machine perfusion (A), the organ sits in an organ chamber that is connected to a reservoir that 
drains the perfusate. In case of dynamic preservation of the liver, dual perfusion of portal vein and 
hepatic artery can be established by separately cannulating these vessels. Often a second pump will 
drive the hepatic artery perfusion (circuit in dotted line) so that different pressure/flow settings can 
be used. During in vivo regional perfusion (B) the pump will drive the perfusate into the donor’s 
arterial circulation, the venous cannulation guarantees return of the perfusate. A heat exchanger 
and oxygenator can be added to the circuit. 
HE, heat exchanger; O2, oxygenator; the arrows denote the direction of flow. 
 
Figure 2: The different dynamic preservation strategies currently entering clinical practice with the 
different modalities of their use. 
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Tables 
Table 1 Overview of ongoing or planned clinical trials in kidney preservation based on search of online clinical trial registries (see  
Table S1: Non-exhaustive list of planned or on-going clinical trials investigating dynamic preservation of kidney or liver that were not registered in an online clinical trial registry at the time of 
writing this manuscript. 
Supplementary Appendix 1). 
Donor type Preservation Endpoint Design Start Status Registration Acronym Lead 
DBD piHMP vs. SCS DGF RCT 08/2005 Analysing ISRCTN35082773 HBD Pump Cambridge, UK – C. Watson 
DBD c/piHMP vs. SCS in 
normothermic and 
hypothermic DBD 
DGF RCT 11/2015 Not yet 
recruiting 
NCT02525510 n.a. San Francisco, USA – D. Malinoski, C. Niemann 
DBD ≥50y HMP 6mo GFR Observational, 
case control 
06/2016 Recruiting NCT02055950 PREDICTION Italy, P. Cravedi 
ECD piHMP 3mo GS open, non-
randomised 
10/2011 Recruiting DRKS00000121 n.a. Essen, Germany – A. Paul, A. Gallinat 
ECD piHMP+O2 vs. SCS 1y GS RCT 05/2014 Recruiting ISRCTN63852508 COPE-POMP COPE – A Paul, T. Minor, P. Kocabayoglu, R. Ploeg 
ECD c/piHMP vs. SCS DGF RCT 04/2010 Recruiting NCT01170910 IMPULSION Lyon, France – L. Badet 
DCD III cHMP vs. SCS DGF RCT 04/2011 Recruiting ISRCTN50082383 CAD-MP Cambridge, UK – C. Watson, D. Summers 
DCD III ≥50y cHMP+O2 vs. cHMP 1y GS RCT 01/2014 Recruiting ISRCTN32967929 COPE-COMPARE COPE – J. Pirenne, I. Jochmans, R. Ploeg 
Deceased HMP vs. HMP with 
eternacept 
DGF, 
12mo GS 
RCT 04/2011 Recruiting NCT01731457 n.a. Poland – P. Domagala, A. Kwiatkowski 
CAD-MP; cardiac death – machine perfusion; cHMP, continuous hypothermic machine perfusion; COMPARE, cold oxygenated machine perfusion of aged renal grafts; COPE, consortium for 
organ preservation in Europe; DBD, donation after brain death; DCD, donation after circulatory death; DGF; delayed graft function; ECD, expanded criteria donor; EVNP, ex vivo normothermic 
perfusion; GS, graft survival; HBD, heart beating donor; O2, oxygen; piHMP, pre-implantation hypothermic machine perfusion; piNMP, pre-implantation normothermic machine perfusion; 
POMP, pulsatile oxygenated machine perfusion; RCT, randomised controlled trial; SCS, static cold storage
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Table 2 Overview of ongoing or planned clinical trials in liver preservation based on search of online clinical trial registries (see  
Table S1: Non-exhaustive list of planned or on-going clinical trials investigating dynamic preservation of kidney or liver that were not registered in an online 
clinical trial registry at the time of writing this manuscript. 
Supplementary Appendix 1). 
Donor type Preservation Endpoint Design Start Status Registration Acronym Lead 
DBD piHMP+O2 vs. 
SCS  
Postop 
complications 
(Clavien-Dindo 
class III-IV) 
RCT 09/2011 Recruiting NCT01317342 HOPE Zürich, Switzerland – P. Dutkowski 
DCD piHMP+O2 6mo GS Pilot 04/2014 Completed NTR4493 Dual HOPE Groningen, The Netherlands – R. 
Porte 
DCD piHMP+O2 vs. 
SCS 
IBS on 6mo 
MRCP 
RCT 10/2015 Recruiting NCT02584283 Dual HOPE Groningen, The Netherlands – R. 
Porte 
DBD + DCD III cNMP 30d GS Historic 
control 
10/2012 Completed ISRCTN14355416 n.a. London, UK – N. Heaton 
DBD + DCD III cNMP vs. SCS Peak AST RCT 04/2014 Recruiting ISRCTN39731134 COPE-
WP2 
COPE, P. Friend, D. Nasralla, R. 
Ploeg 
Deceased NMP EAD Matched 
controls 
07/2015 Recruiting NCT02515708 n.a. Cleveland, USA – C. Quintini 
Deceased NMP Safety Pilot 06/2015 Recruiting 
imminent 
NCT02449694 REVIVE Leeds, UK – M. Attia 
Deceased NMP vs. SCS EAD 
serious adverse 
events 
RCT 09/2015 Recruiting 
imminent 
NCT02522871 OCS Liver 
PROTECT 
Trial 
n.a. 
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cNMP, continuous normothermic machine perfusion; COPE, consortium for organ preservation in Europe; COR, controlled oxygenated rewarming; DBD, donation after brain death; DCD, 
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